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Summary
AIM: Various scoring systems aim to assess the quality
of organs donated for transplantation on the basis of pa-
tient characteristics, clinical examination and laboratory
results. How well such scoring systems reflect the practice
in lung transplantation in Switzerland has never been stud-
ied. Therefore, we evaluated two scoring systems for their
ability to predict whether or not donor lungs are accepted
by the two Swiss lung transplant centres.
METHODS: We retrospectively analysed patient data of
adult deceased organ donors in Switzerland between 1
July 2007 and 30 June 2014. Included were all donors
from whom at least one organ was transplanted. We eval-
uated two lung donor quality scores, the multicentre-devel-
oped Eurotransplant donor score (EDS), and the single-
centre-developed Zurich donor score (ZDS). Both scores
were slightly adapted to be applicable to Swiss deceased
organ donor data. We evaluated whether these scores
can predict whether lungs were transplanted or refused by
Swiss transplant centres, using univariate logistic regres-
sion. We further assessed their discriminative power by
calculating the area under the receiver operating charac-
teristic curve (AUC).
RESULTS: Of the 635 donors included in our analysis,
295 (46%) were accepted as lung donors by one of the
two lung transplant centres in Switzerland. Our analysis
showed that both scores can predict whether or not a
donor lung is likely to be accepted for transplantation in
Switzerland. As the score value of a donor increases,
the odds of the lung being transplanted significantly de-
creases (odds ratio [OR] 0.58, 95% confidence interval
[CI] 0.51–0.65 for the adapted EDS; OR 0.35, 95% CI
0.28–0.43 for the adapted ZDS). This effect is slightly
more pronounced in the adapted ZDS than in the adapted
EDS. The discriminatory power of the scores from the
AUC was 0.719 (95% CI 0.680–0.758) for the adapted
EDS, and 0.723 (95% CI 0.681–0.760) for the adapted
ZDS, which for both was deemed fair discrimination.
CONCLUSIONS: Both scoring systems are able to predict
whether or not donor lungs are accepted by the two Swiss
lung transplant centres. As an alternative to adapting an
established scoring system, a national lung quality score
could be derived de novo. This could be based on a logis-
tic regression analysis including the most relevant donor
characteristics. However, such a new score would need to
be validated on an independent sample and ideally tested
for its predictive value in terms of post-transplantation out-
come.
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Introduction
Donor lungs for transplantation are a scarce resource. One
possibility for expanding the donor pool is to consider ex-
tended-criteria donors – sometimes also called marginal
donors – as potential donors. These are donors with con-
ditions that might limit the chance of successful donation
and transplantation [1]. In the light of ever growing waiting
lists worldwide, the use of extended-criteria donors has be-
come more widely accepted, not only in the field of lung
transplantation [2–6].
However, there is no international consensus on a defined
set of criteria for extended-criteria donors, nor are there
any standardised thresholds for individual criteria [1]. In
Europe, no evidence-based studies exist to assist the defin-
ition of an extended-criteria donor, which is why different
transplant programmes and transplant centres use differ-
ent concepts of an extended-criteria donor [1]. In Switzer-
land, the current practice of using extended-criteria donors
in lung transplantation draws on concepts that are guided
by a publication of Orens and colleagues in 2003 [6]. Since
then, organ viability criteria have been continually adjusted
and refined, according to the experience of professionals in
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lung transplantation. These adaptations were based on the
current clinical practice and literature, and also accounted
for changes within the population constituting the current
donor pool.
There are scoring systems aiming to assess the quality of
donor lungs for transplantation based on the risks of poten-
tially compromised organ function in the recipient. Most of
these risk scoring systems also include one or several ex-
tended donor criteria [1]. In the present study, we evaluated
two different donor quality scores in a retrospective analy-
sis of Swiss donor data [7, 8]. We evaluated whether these
scores can discriminate between lungs that were procured
and transplanted and lungs that were refused by Swiss
transplant centres – in other words, whether the score val-
ues reflect the likelihood that a lung is deemed to be trans-
plantable by Swiss experts in lung transplantation.
Methods
Donor data
Comprehensive and compulsory donor data as captured by
the donor hospital staff with the national online application
“Swiss Organ Allocation System” (SOAS) were retrospec-
tively analysed. Included were all Swiss deceased donors
from whom at least one organ was transplanted (utilised
donors) from 1 July 2007 to 30 June 2014 (n = 695). Data
entry was under the supervision of Swisstransplant to guar-
antee compliance with the Swiss Transplantation Law and
to enable comparable data quality among different donor
hospitals. Both donors after brain death and donors after
cardiocirculatory death were included.
Excluded from the subsequent analysis were donors below
the age of sixteen (n = 23) and donors whose lungs were re-
fused by Swiss transplant centres for reasons not primarily
related to the donor’s medical condition or to organ quali-
ty (n = 37). These non-medical refusal reasons include ab-
sence of consent by donor/family (specific exclusion of the
lung from transplantation as documented with a donor card
or expressed by the next of kin; n = 23), logistic reasons (n
= 2), procurement accidents (n = 1) and absence of a com-
patible Swiss recipient (n = 11). The last was mostly due
to organ size and weight mismatch, blood group incompat-
ibility or an incompatible virology status between donor
and recipient and includes nine donors whose lungs were
eventually transplanted abroad.
The term “accepted lung donor” in this article refers to a
donor from whom at least one lung lobe was transplanted
in Switzerland. Likewise, the term “refused lung donor”
refers to the refusal of both donor lungs in Switzerland pri-
marily for donor-related medical reasons. Figure 1 shows
derivation and composition of analysed cases.
Adapted Eurotransplant donor score
Smits et al. [7] described the development and the eval-
uation of a quality scoring system for lung donors based
on a previous publication by Oto et al. [9]. They derived
this Eurotransplant donor score (EDS) through a retrospec-
tive analysis of different extended donor criteria, which
Figure 1: Flowchart of all utilised Swiss deceased donors 2007–2014. The group “lungs transplanted in Switzerland” included double (n =
285), left (n = 3) and right (n = 6) lung transplants and one split lung transplant.
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were weighted with points according to the odds ratio
of whether the lung was accepted or discarded. For each
donor, a score was obtained by adding these points: a low
score reflects a good quality donor. The EDS thus reflects
the aggregated perceived risk of several experts in lung
transplantation in various centres in the Eurotransplant net-
work in the period from 1999–2007 [7].
Some of the clinical tests performed in the Eurotransplant
allocation programme are not routinely performed in
Switzerland or their recording in the national database
SOAS is not compulsory when reporting a donor. Because
of such differences in data capture, the original EDS had to
be slightly adapted for the present analysis (aEDS). In the
following paragraphs we describe how the EDS was adapt-
ed to enable application on Swiss donor data:
− Donor history/cancer: In the EDS, the criterion “donor
history” summarises data on several predefined extended-
criteria donor conditions without specifying. These extend-
ed-criteria donor conditions include previous history of
malignancy, sepsis, drug abuse, or meningitis, and a posi-
tive virology [7]. In the SOAS, specific donor data on sep-
sis, drug abuse and meningitis are not available. Data on
positive virology (human immunodeficiency virus, hepati-
tis B virus and hepatitis C virus) were available but were
assumed to bias the score because this is a partial con-
traindication for transplantation in Switzerland. Therefore,
the original criterion “donor history” in our aEDS is lim-
ited to data on cancer (history and active cancer at time
of admission, only types of cancer that are not an absolute
contraindication) and was for this reason renamed “can-
cer”.
− Chest x-ray: In the EDS, this criterion discriminates clear
results from oedema, shadows, atelectasis and consolida-
tion [7]. In the SOAS it is only documented whether the
chest x-ray was “normal” or “not normal”. For our aEDS,
donors reported as “normal” in the SOAS were assumed to
have had a clear x-ray and were assigned one point (as in
the EDS). Donors reported as “not normal” in the SOAS
were assumed to have had a "not clear" x-ray and were as-
signed two points.
− Bronchoscopy: The EDS distinguishes various results
of bronchoscopy (clear, non-purulent, purulent, inflamma-
tion, visualised tumour) [7]. In the SOAS, recording of
bronchoscopy results is not compulsory when reporting a
donor, such that most donor records miss this information.
Therefore, this factor has been excluded from our aEDS
completely.
An overview of the aEDS is given in table 2 in the results
section.
Adapted Zurich donor score
Like the EDS, the Zurich donor score (ZDS) is an ag-
gregated quality measurement for the assessment of donor
lungs. It was developed at the University Hospital of
Zurich, one of two centres for lung transplantation in
Switzerland. The ZDS was based on clinical experience
and expert knowledge, and the criteria are weighted with
either zero or one point. The ZDS originally comprised
five extended donor criteria and five comorbidities, includ-
ing systemic arterial hypertension, cardiac disease, insulin
dependent diabetes mellitus, chronic renal disease and liv-
er disease [8].
For the present analysis, the score has been limited to four
extended-donor criteria, shown in table 3 (below). An age
threshold of 65 years and a value for the ratio of partial
pressure arterial oxygen and fraction of inspired oxygen
(PaO2/FiO2) of 250 mm Hg were found to be most dis-
criminative in a preliminary analysis and therefore used in
our adapted score (aZDS). The score reflects the aggregat-
ed perceived risk of local experts in lung transplantation: a
low score reflects a good quality lung donor.
Statistical analysis
Donors were divided into two groups, lung transplanted
and lung refused in Switzerland. Between these groups,
baseline donor characteristics were compared for quanti-
tative variables by using the t-test, or if the normality as-
sumption was not met, by non-parametric Wilcoxon rank-
sum test. For qualitative variables Pearson’s chi-square test
was used, or Fisher’s exact test when the sample size was
small. If not otherwise indicated, two-sided statistical mod-
els were applied (non-directional hypotheses) and p-values
of less than 0.05 were considered significant. For Wilcox-
on’s rank-sum test, the statistic W, the significance level
(p-value), and the standardised effect size r, which mea-
sures the strength of association (an absolute value of r
>0.1, r >0.3 and r >0.5 means a small, medium and large
effect, respectively) are reported in the text. For the Pear-
son’s chi-square test the statistic χ2 with associated degrees
of freedom (in brackets) and the significance level (p-val-
ue) are reported in the text.
The donor quality scores were considered to be continuous
variables and their effect on lung transplantation in
Switzerland (transplanted/refused) was analysed indepen-
dently, using univariate logistic regression. The ability of
the scores to discriminate between the outcomes (lung
transplanted vs refused) was assessed by calculating the
area under the receiver operating characteristic curve
(AUC). The value of AUC lies between 0.5 and 1.0: 0.5 de-
notes a random predictor and 1.0 denotes a perfect classifi-
er. Values were interpreted as follows: 0.9–1.0 = excellent;
0.8–0.9 = good; 0.7–0.8 = fair; 0.6–0.7 = poor; 0.5–0.6 =
fail [10].
For all statistical analyses, the freely available software R
(version 3.4.1) was used [11].
Results
Donor baseline characteristics
Of the 635 utilised adult donors included in our analysis,
295 were accepted as lung donors by one of the two lung
transplant centres in Switzerland (acceptance rate 46%).
In contrast, 340 donors were refused by the Swiss lung
transplant centres for primarily donor-related medical rea-
sons (refusal rate 54%). Detailed donor characteristics are
shown in table 1.
Accepted lung donors were significantly younger (W =
63048, p <0.001, r = −0.22) and had a significantly lower
body mass index (W = 63048, p <0.001, r = −0.23) than
refused lung donors. All analysed causes of admission to
the intensive care unit (ICU) – except for respiratory arrest
– were significantly associated with the outcome whether
or not the donor lung was accepted by Swiss transplant
centres. The corresponding values of the Pearson’s chi-
square test were: χ2 (1) = 3.92, p <0.05 for cardiac arrest;
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χ2 (1) = 6.45, p <0.05 for reanimation; and χ2 (1) = 5.51, p
<0.05 for trauma. Accepted lung donors died significantly
less often from anoxia compared with refused lung donors:
χ2 (1) = 5.05, p <0.05. Conversely, cerebral trauma was
significantly more common in accepted lung donors than
in refused lung donors: χ2 (1) = 5.23, p <0.05. Of seven
analysed comorbidities, three were found to be significant-
ly less common in accepted lung donors than in refused
lung donors: heart disease, χ2 (1) = 10.07, p <0.05; lung
disease, χ2 (1) = 21.99, p <0.001; and liver disease, χ2 (1)
= 8.10, p <0.05.
Composition of scores
Table 2 shows how the aEDS is built and how the different
criteria are weighted. The distribution of individual criteria
between the two donor groups of accepted and refused
lung donors is presented. The same is shown for aZDS in
table 3.
Score evaluation
The frequency distribution of adapted score values for
lungs transplanted versus refused is shown in figure 2 for
aEDS, and in figure 3 for aZDS. Whether the adapted
scores can predict whether a donor lung is accepted or re-
fused in Switzerland was evaluated using logistic regres-
sion. We found that this held true for both scores: As the
score of a donor increased, the odds of the lung being
transplanted in Switzerland significantly decreased. This
effect was slightly more pronounced with the aZDS than
with the aEDS. Detailed results of both logistic regression
models are shown in table 4.
Based on the logistic regression models, expected proba-
bilities for each score value were calculated. The probabil-
ity of a lung being transplanted from a donor with an aEDS
of five (best score) was 82%, whereas from a donor with
an aEDS of fourteen (worst score) this probability was 3%.
The probability of a lung being transplanted from a donor
with an aZDS of zero (best score) was 77%, whereas for a
donor with an aZDS of four (worst score) this probability
was 5%. Expected probabilities are presented by score val-
ues in figure 4 (aEDS) and figure 5 (aZDS).
The discriminatory power of the scores using the AUC was
0.719 (95% CI 0.680–0.758) for aEDS and 0.723 (95% CI
0.681–0.760) for aZDS, which for both was deemed a fair
discrimination (interpretation of AUC values see methods
section).
Discussion
Score evaluation
We evaluated two established scoring systems for the qual-
ity assessment of donor lungs by analysing Swiss organ
Figure 4: Probability of a donor lung being transplanted in Switzer-
land according to adapted Eurotransplant donor score (aEDS),
based on a logistic regression model.
Table 1: Donor baseline characteristics for accepted and refused lung donors.
Accepted lung donors
n (%)
Refused lung donors
n (%)
p-value
Total 295 (46%) 340 (54%)
Male 169 (57%) 196 (58%)
Female 126 (43%) 144 (42%)
0.927
Age (median and IQR; years) 51.0 (38.0–62.0) 59.0 (47.0–68.0) <0.001**
BMI (median and IQR; kg/m2) 24.2 (22.6–26.0) 25.7 (23.5–27.8) <0.001**
Cause of admission to ICU
Trauma 84 (30%) 69 (22%) 0.019*
Cardiac arrest 73 (25%) 109 (32%) 0.048*
Respiratory arrest 65 (22%) 97 (29%) 0.060
Reanimation 56 (21%) 97 (30%) 0.011*
Cause of death
Cerebral haemorrhage 171 (58%) 200 (59%) 0.827
Cerebral trauma 70 (24%) 56 (16%) 0.022*
Anoxia 49 (17%) 81 (24%) 0.025*
Other 5 (2%) 3 (1%) 0.360
Comorbidities
Hypertension 126 (44%) 120 (38%) 0.116
Heart disease 46 (16%) 85 (26%) 0.002*
Diabetes mellitus 17 (6%) 33 (10%) 0.056
Lung disease 14 (5%) 55 (17%) <0.001**
Kidney disease 11 (4%) 13 (4%) 0.883
Liver disease 8 (3%) 26 (8%) 0.004*
Cancer 6 (2%) 9 (3%) 0.540
BMI = body mass index; ICU = intensive care unit; IQR = interquartile range For cause of admission to ICU and comorbidities more than one item per donor is possible such that
percentages do not add up to 100. Donor characteristics with p-values below 0.05 are considered to differ significantly between the groups of accepted vs refused lung donors. *
p <0.05, ** p <0.001
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Figure 5: Probability of a donor lung being transplanted in Switzer-
land according to adapted Zurich donor score (aZDS), based on a
logistic regression model.
donor data from 1 July 2007 until 30 June 2014. We found
that both scoring systems (adapted to data available) were
able to predict which donors are likely to be accepted
for transplantation in Switzerland. The higher a particular
donor “scores”, the more likely it is that the lung will be
refused by the Swiss lung transplant centres. This finding
basically holds true for both centres. A preliminary analy-
sis showed a similar score distribution of transplanted and
refused donors in both lung transplant centres. Therefore,
the results of the preliminary analysis suggested that donor
assessment and selection was carried out according to very
similar criteria, yielding a donor selection that was similar
over the entire study period. Thus, our study was designed
Table 2: Composition of the adapted Eurotransplant donor score (aEDS) for accepted vs refused lung donors.
Criteria Score points
(aEDS)
Accepted lung donors
n (%)
Refused lung donors
n (%)
Total 1–15 295 (46%) 340 (54%)
Donor age (years)
<55 1 168 (57%) 139 (41%)
55–59 2 36 (12%) 38 (11%)
≥60 3 91 (31%) 163 (48%)
Cancer*
No 1 285 (97%) 313 (92%)
Yes 4 6 (2%) 9 (3%)
Not available 1 4 (1%) 18 (5%)
Smoking history
No 1 146 (49%) 115 (34%)
Yes 2 133 (45%) 200 (59%)
Not available 1 16 (5%) 25 (7%)
Chest x-ray*
Normal 1 148 (50%) 79 (23%)
Not normal 2 142 (48%) 240 (71%)
Not available 1 5 (2%) 21 (6%)
PaO2/FiO2 (mm Hg)
>350 1 166 (56%) 82 (24%)
301–350 2 45 (15%) 42 (12%)
≤300 3 61 (21%) 141 (41%)
Not available 2 23 (8%) 75 (22%)
PaO2/FiO2 = ratio of partial pressure arterial oxygen and fraction of inspired oxygen * Definition differs from the original EDS. The criterion “bronchoscopy” in the original EDS was
excluded in the adapted version (see methods section for details).
Table 3: Composition of the adapted Zurich donor score (aZDS) for accepted vs refused lung donors.
Criteria Score points
(aZDS)
Accepted lung donors
n (%)
Refused lung donors
n (%)
Total 0–4 295 (46%) 340 (54%)
Donor age (years)
<65 0 244 (83%) 224 (66%)
≥65 1 51 (17%) 116 (34%)
Smoking history (pack-years*)
<20 0 197 (67%) 149 (44%)
≥20 1 62 (21%) 122 (36%)
Not available 0 36 (12%) 69 (20%)
Chest x-ray
Normal 0 148 (50%) 79 (23%)
Not normal 1 142 (48%) 240 (71%)
Not available 0 5 (2%) 21 (6%)
PaO2/FiO2 (mm Hg)
>250 0 245 (83%) 158 (46%)
≤250 1 27 (9%) 107 (31%)
Not available 0 23 (8%) 75 (22%)
PaO2/FiO2 = ratio of partial pressure arterial oxygen and fraction of inspired oxygen * Pack-years are the number of cigarette packs smoked per day multiplied by the number of
years smoking. The original ZDS comprises five extended donor criteria and five comorbidities. The adapted version of the score has been limited to four extended donor criteria
(see methods section for details).
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to analyse national data and not to compare the two Swiss
lung transplant centres.
Interestingly, the aZDS, which includes only four criteria
selected solely on the basis of expert opinion, has as much
discriminative power as the aEDS, which includes five
criteria selected on the basis of results of a detailed sta-
tistical analysis (the discriminative power of aZDS was
even found to be slightly higher than the one of aEDS
even though not significantly). In other words, the aZDS
may lack a statistics-based methodology compared with
the aEDS, but transplant teams could apply both scores
Figure 2: Adapted Eurotransplant donor score frequency distribution for accepted lung donors (blue) vs refused lung donors (grey). Arrows
show the interquartile ranges (IQRs) of the score distribution of each group.
Figure 3: Adapted Zurich donor score for accepted lung donors (blue) vs refused lung donors (grey). Arrows show the interquartile ranges
(IQRs) of the score distribution of each group.
Table 4: Results of two independent binary logistic regression models including the adapted Eurotransplant donor score (aEDS) and adapted Zurich donor score (aZDS), each
as a single predictor for being transplanted in Switzerland.
B (SE) p-value Odds ratio
(95% CI)
R2
Model 1 (lung transplanted ~ aEDS) −0.55 (0.06) <0.001 0.58 (0.51–0.65) 0.11
Model 2 (lung transplanted ~ aZDS) −1.04 (0.11) <0.001 0.35 (0.28–0.43) 0.13
R2 = McFadden
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equally in their assessment of donor quality, with the aZDS
being easier and faster to calculate.
However, according to our interpretation of the AUC val-
ues, the discriminative power of both scores was rather
fair than good – and was definitely far from excellent. In
practice, donors with high score values were transplanted,
and others with low score values were refused. Particular-
ly, donors with score values in the mid-range of the score
distribution (e.g., donors with an aEDS of eight or an aZDS
of one) are almost as likely to be transplanted as refused.
This result, however, is not unexpected. There are numer-
ous criteria that possibly can affect organ quality, and the
criteria that build the scores are only a few of them. Al-
so, organ quality is usually only one aspect considered in
transplantation. The expert’s decision as to whether a par-
ticular donor lung is accepted or refused is always taken
in the specific context of the recipient. In our analysis we
included only donor-related refusal reasons as they were
documented in the SOAS. However, in practice when a
donor is refused, unambiguous designation of the refusal
reason as donor-related or recipient-related is sometimes
difficult. Additionally, and as also acknowledged by Smits
and colleagues [7], these scores are derived from prepro-
curement values and therefore do not account for results
of the physical examination of the lung at the time of re-
trieval.
Use of donor quality scores
Policymakers in Switzerland urge a national benchmarking
system between different transplant centres. In order to op-
timise objectiveness, such a system would need to consider
all risk factors that may influence the transplant outcome
and would have to adjust for these risks as effectively as
possible. To develop a risk-adjusted benchmarking system,
it is essential to identify donor and recipient factors that
possibly impact the centres’ outcome data. A donor quality
scoring system that includes the most prominent donor risk
factors for compromised graft function could possibly help
facilitate risk adjustment of post-transplant outcome analy-
ses, at least on the donor side. However, it is important to
point out that the adapted donor quality scores evaluated in
this study do not qualify for comparative outcome analy-
ses since they have not been validated with recipients’ out-
come data.
Instead, use of the scores could possibly support experts in
their assessment of donor quality by providing them with
a quantitative measure based on their own perceived risk
from past practice. However, whether a potential donor or-
gan should be accepted or refused for a particular recipient
can only be decided after consideration of all the case-spe-
cific circumstances. Nevertheless, a donor risk score might
also help to choose the right donor for the right recipient
when the risk of an adverse transplant outcome and the risk
of dying on the waiting list must be gauged.
Swiss performance compared with other countries
A straightforward international comparison on the basis of
the EDS is not feasible as we had to use an adapted version
of the score. However, the overall lung acceptance rate by
the two Swiss lung transplant centres was relatively high
(46% over the entire study period). For comparison, ac-
ceptance rates in 2014 for donor lungs were 41% in Ger-
many, 23% in the USA, 21% in France and only 9% in
Italy [12]. Although these are remarkable differences, no
comparative studies aiming to explain them are available
in the literature according to the authors’ knowledge. In a
Belgian study of extended-criteria donor lung donors, the
authors stated that, worldwide, only 15–25% of all multior-
gan donors have lungs suitable for lung transplantation be-
cause of serious injury following cardiopulmonary resus-
citation, lung contusion, airway aspiration and pulmonary
infection at the time of brain insult, as well as underlying
lung disease [13]. In the same publication, a lung accep-
tance rate in the Belgian transplant network of around 40%
for 2012 was reported, which is fairly similar to Switzer-
land. The authors partly explain this number by the density
of hospitals in their country, which allows the procurement
team to drive to all hospitals by car within 2 hours to check
the quality of the donor lung on site.
Other possible factors potentially influencing acceptance
practice may be waiting list composition, allocation
modalities, and national or individual centre guidelines. It
is important to note that the lung allocation modality in
Switzerland incorporates no medical preselection by Swis-
stransplant. In other words, all donor lungs offered are
made available to the transplant centres and, therefore, the
acceptance rate we report directly represents the centres’
practices. Another possible explanation for the relatively
high lung acceptance rate may be that Switzerland has a
rather low organ donation rate [14], but also an excellent
healthcare system. Owing to the low donation rate, there
is a great imbalance between supply (organs donated for
transplantation) and demand (patients on the waiting list).
This imbalance may lead to a higher overall acceptance of
grafts, as the pressure to meet the needs of patients await-
ing transplantation may be higher. It is noticeable in this
context that Switzerland and Germany share both a rela-
tively low organ donation rate and a relatively high lung
acceptance rate.
Whatever the reasons for the relatively high lung accep-
tance rate in Switzerland may be, it is of particular interest
since some of the most important characteristics of Swiss
lung donors considered relevant for graft function (e.g.,
age, history of smoking) are rather far from what is gener-
ally regarded as ideal. Seventeen percent of accepted Swiss
lung donors in the study period were 65 years or older,
whereas only 10% of European (data for 2015/2016), and
only 1% of US lung donors were in the same age group
[15, 16]. The percentage of US lung donors with a smok-
ing history of 20 pack-years or more has more than halved
since 2004, being as low as 10% on average during our
study period (2007–2014) [17]. Our data show that the per-
centage of Swiss lung donors with a reported smoking his-
tory of 20 pack-years or more was on average 21% − more
than twice as high as in the US.
The international comparison of donor characteristics and
acceptance rates suggests that the relatively high yield of
donor lungs in Switzerland (46% transplanted) may be a
result of an extensive use of extended-criteria donors. This
raises the question of whether the relatively frequent use
of “non-ideal” donors in Switzerland poses additional risks
to Swiss lung recipients. However, if one compares Swiss
lung post-transplantation outcome data (not part of this
study) with international outcome data, the answer to this
question is no. Overall mortality of Swiss lung transplant
recipients is very similar to available European data, be-
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ing 26.4% in Switzerland, and 27.7% in Europe at 3-years
post-transplant [18, 19]. The 1-year post-transplant mortal-
ity in Switzerland is even lower than the European average,
11.7 and 16.9%, respectively [18, 19].
Limitations of the study
Our study has several limitations, which are mainly related
to data availability. The attempt to apply the original EDS
on Swiss donor data showed that it is not straightforward
to use a scoring system that includes results of complex
clinical tests, and that was developed elsewhere. In reality,
clinical examinations often follow different guidelines and
procedures, and therefore vary from country to country,
sometimes even between centres. Also, how the data are
captured can vary depending on the instruments and com-
puter software in use. In addition to that, the interpretation
of some clinical examinations (such as x-ray or bron-
choscopy) is to some extent subjective. In our study, it
was not possible to use the original EDS because data cap-
ture in the Swiss transplantation programme was not of the
same as Eurotransplant’s for some of the clinical criteria.
Eurotransplant was confronted with the same issue when
they tried to evaluate the Oto Score – indeed, it was the
lack of detailed data needed for the calculation of the Oto
Score that led them to develop their own scoring system,
based on their available data [7].
It was the aim of our study to evaluate two established lung
donor scores and not to develop a national score de no-
vo. According to our analysis of donor baseline character-
istics (table 1) there are several criteria that differ signifi-
cantly between accepted and refused lung donors and are
not included in either of the scores (body mass index, some
specific causes of admission and death, some comorbidi-
ties). The criterion cancer is included in the aEDS, but we
found no significant difference between accepted and re-
fused lung donors. Thus, based on our results for Switzer-
land, the scores could be improved by incorporating more
of the criteria that show significant differences, and by re-
moving criteria which are not significantly different be-
tween transplanted and refused lung donors. Alternatively,
donor or organ characteristics could be tested stepwise in
a multivariate logistic regression model. Hence one could
theoretically also derive a distinct Swiss lung donor quali-
ty score using a similar methodology as described by Smits
et al. [7]. However, a new score would need careful valida-
tion by application to an independent cohort, and ideally by
evaluating its predictive value for post-transplantation out-
come (graft failure, patient survival). Such outcome analy-
ses would need to control for a number of factors that prob-
ably also have a major impact on the post-transplantation
outcome, such as ischaemia time, surgical aspects, and re-
cipient selection criteria and medical condition at the time
of transplantation.
Conclusions
The scores evaluated in this study are able to predict the
likelihood that a donor lung is deemed transplantable by
Swiss experts in lung transplantation. However, applying
scoring systems that were developed from single-centre
data or abroad to a national level requires careful adapta-
tion to available data prior to their use in clinical practice.
As an alternative to adapting established scores, our analy-
sis of donor characteristics could also serve as a basis for
the derivation of a national quality score de novo. Such a
new score would need to be validated on an independent
sample and ideally tested for its predictive value in terms
of post-transplantation outcome. Further studies could fo-
cus on outcome by including not only donor criteria but
also ischaemia time, surgical aspects and the medical sit-
uation of the recipient at time of transplantation. A multi-
variate analysis of these factors may be of interest.
Donor lung utility in Switzerland is high compared with
most other European countries or the USA despite a rela-
tively low average organ quality in the Swiss lung donor
pool. Yet, post-transplantation outcomes are overall com-
parable to other countries, which emphasizes the excellent
quality of care of the Swiss lung transplant programme.
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